Clinical pharmacology of thiopropium bromide


Cite item

Full Text

About the authors

A N Tsoi

V V Arkhipov

References

  1. Pharmacological sciences 1996 receptor and ion channel nomenclature supplement. 7th ed. New York: Elsevier Science; 1996. 5.
  2. Middleton Allergy: Principles and practice. 5th ed. St. Louis: Mosby-Year Book; 1998. 668-670.
  3. Disse В., ReicI R., Speck G. et al. Ba B79 BR, a novel longacting anticholinergic bronchodilator. Life Sci. 1993: 52: 537- 544.
  4. Haddad E.-B., Mak J. C., Barnes P. J. Characterisation of [3H]-Ba-679 BR, a slowly dissociating muscarinic antagonist in human lung: Radioligand binding and autoradiographic mapping. Mol. Pharmacol. 1994; 45: 899-907.
  5. Takahashi Т., Belvisi M. G., Patet H. et al. Effect of Ba 679 BR, a novel longacting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am. J. Respir. Crit. Care Med. 1994; 150: 1640-1645.
  6. Reichl R., Traunecker W. Pharmacological profile of BA 679 BR, a new long acting anticholinergic bronchodilator. Naunyn-Schmiedeberg's Arch. Pharmacol. 1993; 347 (suppi.): abstr. 445.
  7. Disse В., Speck G. A., Rominger K. L. et al. Tiotropium (SpirivaTM): Mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64: 457-464.
  8. Witek T. J., Souhrada J. F., Serby С. W., Disse B. Tiotropium bromide (Ba 679), pharmacology and early clinical observations. Lung Biol. Hlth 1999; 134: 137-152.
  9. Disse В., Rominger K., Serby C. W. et al. The pharmacokinetic (PK) profile of tiotropium during longterm treatment in stable COPD. Am. J. Respir. Crit Care Med. 1999; 159 (3, pt 2): A524.
  10. Global initiative for chronic obstructive lung disease. National Heart, Lung, and Blood Institute. Publication Number 2701. March 2001.
  11. NHLBI/WHO Workshop report: Global strategy for asthma management and prevention. NIH Publication No. 02-3659. Feb. 2002.
  12. Maesen F. P., Smeets J. J., Costongs M. A. et al. Ba-679-Br, a new long-acting antimuscarinic bronchodilator: A pilot doseescalation study in COPD. Eur. Respir. J. 1993; 6: 1031 - 1036.
  13. Maesen F. P., Smeets J. J., Sledsens T. J. et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Ibid. 1995; 8: 1506-1513.
  14. O'Connor B. J., Towse L. J., Barnes P. J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1996; 154: 876-880.
  15. Noveck R., Haynes E., Koker P. et al. Bronchodilator effect of tiotropium in moderate-severe athmatics. Ibid. 1999; 159 (3, pt 2): A625.
  16. Casaburi R., Serby С. W., Menjoge S. S., Witek T. J. The spirometric efficacy of once daily dosing with tiotropium in stable COPD. Ibid. A524.
  17. van Noord J., Bantje Т., Eland M. et al. Superior efficacy of tiotropium (TIO) compared to ipratropium (IpBr) as a maintenance bronchodilator in COPD. Ibid. A525.
  18. San Pedro G., Elias D. J., Serby С. W., Witek T. J. Tiotropium (SpirivaTM): One year bronchodilator efficacy established with once daily dosing in COPD patients. Ibid. 2000; 161 (3, pt 2): A749.
  19. Mahler D. A., Montner P., Brazinsky S. A. et al. Tiotropium (SpirivaTM), a new long-acting anticholinergic bronchodilator, improves dyspnea in patients with COPD. Ibid. A892.
  20. van Noord J., Bantje Т., Eland M. et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of COPD. Thorax 2000; 55: 289-294.
  21. Donohue J. F., van Noord J. A., Bateman E. D. et al. A 6month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
  22. Vincken W., van Noord J. A., Greefhorst A. P. M. et al. Improved health outcomes in patient with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.
  23. Casaburi R., Mahler D. A., Jones P. W. et al. A long-term evalution of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Ibid. 217-224.
  24. Kotch A., Menjoge S. S., Serby С. W., Kesten S. Nocturnal symptoms and severity of disease in COPD. Am. J. Respir. Crit. Care Med 2001; 163 (5): 906.
  25. McNicholas W. Т., Calverley P. M. A., Edwards C., Lee A. Effects of anticholinergic therapy (tiotropium) on REM-related desaturation and sleep quality in patients with COPD. Ibid. 280.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies